Business
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in ...
About this update from Medicure Inc.
[{"type":"text","content":"WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2026 and will have a conference call to present the Financial Results on May 25, 2026 at 8:30 am Eastern Time.","length":480,"tagName":"p"},{"type":"text","content":"Quarter Ended March 31, 2026 Highlights:","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Recorded total net revenue of $7.9 million during the period ended March 31, 2026 compared to $5.4 million for the period ended March 31, 2025 and;","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Recorded total net revenue from the sale of ZYPITAMAG® of $2.3 million ($1.3 million through the traditional insured channels, and $1.0 million through Marley Drug) during the period ended March 31, 2026 compared to $1.4 million ($519,000 through the traditional insured channels, and $918,000 through Marley Drug) for the period ended March 31, 2025 and;","length":355,"tagName":"p"}]},{"val":[{"type":"text","content":"Recorded total net revenue from the sale of AGGRASTAT® of $979,000 during the period ended March 31, 2026 compared to $1.7 million during the period ended March 31, 2025 and;","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"The Pharmacy Business Segment, which includes Marley Drug, and the Company's two recently acquired pharmacies (purchased in 2025), Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $5.7 million ($1.0 million from sales of ZYPITAMAG®, and $4.7 million from other pharmacy revenue) during the period ended March 31, 2026 compared to net revenue of $3.3 million ($918,000 from sales of ZYPITAMAG®, and $2.3 million from other pharmacy revenue) during the period ended March 31, 2025 and;","length":520,"tagName":"p"}]},{"val":[{"type":"text","content":"Medicure invested $855,000 in research and development during the period ended March 31, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of Medicure's investigational product MC-1 for the treatmen...